Skip to content

Nanoform’s collaboration with TargTex

TargTex CEO João Seixas discusses the value Nanoform’s CESS technology delivered for TargTex’s novel drug candidate targeting glioblastoma, one of the most common and aggressive types of primary brain tumor. The partnership with Nanoform was critical in achieving success at this stage, with hope the product can now be taken further into clinical development.